Radiopharmaceuticals play a niche role in treating cancer, despite having labels in multiple oncology indications in the US and EU,…
Amryt Pharma’s Juxtapid (lomitapide) had a 7-point jump in its Likelihood of Approval (LoA) in familial chylomicronaemia syndrome (FCS) on the heels of positive data from an investigator-led Phase III…
Johnson & Johnson’s Phase III double-dose Covid-19 vaccine prompted a range of expert analyses as to how the prime-boost regimen would be rolled out considering the single-dose approach is already…
The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data. The score change was…
Provention Bio’s teplizumab for delaying type 1 diabetes (T1D) will have to grapple with formulating and implementing an effective screening strategy and its ensuing costs, experts said. There is no…
Relief Therapeutics’ RLF-100 (aviptadil) received an 11-point boost in its likelihood of approval (LoA) as of 30 March, after the company announced a positive Phase II/III study in Covid-19. Relief…
Theravance Biopharma’s Phase III trial investigating ampreloxetine in symptomatic neurogenic orthostatic hypotension (nOH) may find it challenging to demonstrate real-world relevant results despite a clinically relevant primary endpoint, experts said.…